Mutational Analysis of Merkel Cell Carcinoma

Merkel cell carcinoma (MCC) is an aggressive cutaneous neuroendocrine malignancy that is associated with a poor prognosis. The pathogenesis of MCC is not well understood, and despite a recent plethora of mutational analyses, we have yet to find a set of signature mutations implicated in the majority...

Full description

Bibliographic Details
Main Authors: Derek J. Erstad, James C. Cusack
Format: Article
Language:English
Published: MDPI AG 2014-10-01
Series:Cancers
Subjects:
Online Access:http://www.mdpi.com/2072-6694/6/4/2116
id doaj-93072b5f48694e2291cc1381f9d0cb04
record_format Article
spelling doaj-93072b5f48694e2291cc1381f9d0cb042020-11-24T20:47:57ZengMDPI AGCancers2072-66942014-10-01642116213610.3390/cancers6042116cancers6042116Mutational Analysis of Merkel Cell CarcinomaDerek J. Erstad0James C. Cusack1Department of Surgery, Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114, USADivision of Surgical Oncology, Harvard Medical School, Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114, USAMerkel cell carcinoma (MCC) is an aggressive cutaneous neuroendocrine malignancy that is associated with a poor prognosis. The pathogenesis of MCC is not well understood, and despite a recent plethora of mutational analyses, we have yet to find a set of signature mutations implicated in the majority of cases. Mutations, including TP53, Retinoblastoma and PIK3CA, have been documented in subsets of patients. Other mechanisms are also likely at play, including infection with the Merkel cell polyomavirus in a subset of patients, dysregulated immune surveillance, epigenetic alterations, aberrant protein expression, posttranslational modifications and microRNAs. In this review, we summarize what is known about MCC genetic mutations and chromosomal abnormalities, and their clinical significance. We also examine aberrant protein function and microRNA expression, and discuss the therapeutic and prognostic implications of these findings. Multiple clinical trials designed to selectively target overexpressed oncogenes in MCC are currently underway, though most are still in early phases. As we accumulate more molecular data on MCC, we will be better able to understand its pathogenic mechanisms, develop libraries of targeted therapies, and define molecular prognostic signatures to enhance our clinicopathologic knowledge.http://www.mdpi.com/2072-6694/6/4/2116merkel cell carcinomamerkel cell polyomavirustumor suppressoroncogeneprognostic algorithmmutational analysis
collection DOAJ
language English
format Article
sources DOAJ
author Derek J. Erstad
James C. Cusack
spellingShingle Derek J. Erstad
James C. Cusack
Mutational Analysis of Merkel Cell Carcinoma
Cancers
merkel cell carcinoma
merkel cell polyomavirus
tumor suppressor
oncogene
prognostic algorithm
mutational analysis
author_facet Derek J. Erstad
James C. Cusack
author_sort Derek J. Erstad
title Mutational Analysis of Merkel Cell Carcinoma
title_short Mutational Analysis of Merkel Cell Carcinoma
title_full Mutational Analysis of Merkel Cell Carcinoma
title_fullStr Mutational Analysis of Merkel Cell Carcinoma
title_full_unstemmed Mutational Analysis of Merkel Cell Carcinoma
title_sort mutational analysis of merkel cell carcinoma
publisher MDPI AG
series Cancers
issn 2072-6694
publishDate 2014-10-01
description Merkel cell carcinoma (MCC) is an aggressive cutaneous neuroendocrine malignancy that is associated with a poor prognosis. The pathogenesis of MCC is not well understood, and despite a recent plethora of mutational analyses, we have yet to find a set of signature mutations implicated in the majority of cases. Mutations, including TP53, Retinoblastoma and PIK3CA, have been documented in subsets of patients. Other mechanisms are also likely at play, including infection with the Merkel cell polyomavirus in a subset of patients, dysregulated immune surveillance, epigenetic alterations, aberrant protein expression, posttranslational modifications and microRNAs. In this review, we summarize what is known about MCC genetic mutations and chromosomal abnormalities, and their clinical significance. We also examine aberrant protein function and microRNA expression, and discuss the therapeutic and prognostic implications of these findings. Multiple clinical trials designed to selectively target overexpressed oncogenes in MCC are currently underway, though most are still in early phases. As we accumulate more molecular data on MCC, we will be better able to understand its pathogenic mechanisms, develop libraries of targeted therapies, and define molecular prognostic signatures to enhance our clinicopathologic knowledge.
topic merkel cell carcinoma
merkel cell polyomavirus
tumor suppressor
oncogene
prognostic algorithm
mutational analysis
url http://www.mdpi.com/2072-6694/6/4/2116
work_keys_str_mv AT derekjerstad mutationalanalysisofmerkelcellcarcinoma
AT jamesccusack mutationalanalysisofmerkelcellcarcinoma
_version_ 1716809486262337536